AIM ImmunoTech Inc. Common Stock
Key Metrics
Market Snapshot
About
AIM ImmunoTech Inc. (AIM) is a biotechnology company based in Ocala, Florida, focused on developing immunotherapies. It is best known for its work on Ampligen, an investigational drug initially studied for chronic fatigue syndrome, and for its commercial product Alferon N Injection.
The company operates as an immuno-pharma company engaged in the research and development of therapeutics. Its primary commercial product is Alferon N Injection, a purified, natural-source interferon product approved for the treatment of genital warts. The core of its development pipeline is the drug Ampligen (rintatolimod). This drug is a large, double-stranded RNA molecule designed to modulate the immune system.
AIM is investigating Ampligen for a wide range of conditions beyond its initial focus. Its research targets include multiple cancer types such as pancreatic, ovarian, breast, and colorectal cancers. The company is also studying the drug's potential in treating viral diseases and immune-deficiency disorders, including Hepatitis B, HIV, and post-COVID conditions. Formerly known as Hemispherx Biopharma, the company was founded in 1966 and rebranded to AIM ImmunoTech in 2019, reflecting its focus on advanced immune-modulating therapies.